Related Experiment Video
Updated: Feb 15, 2026
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Echocardiographic Evaluation of the Right Atrial Area Index in Dogs with Pulmonary Hypertension
T Vezzosi1, O Domenech2, M Iacona1
1Department of Veterinary Sciences, University of Pisa, Pisa, Italy.
Background:
Right atrial area (RAA) is a prognostic factor in human patients with pulmonary arterial hypertension (PAH). Reference intervals for RAA have been described in healthy dogs.
Objectives:
To evaluate RAA indexed to the body surface area in dogs with PAH as an indicator of right atrial size, PAH severity and right-sided congestive heart failure (R-CHF).
Animals:
A total of 119 client-owned dogs, 48 dogs with PAH and 71 control dogs.
Methods:
Prospective observational study. Pulmonary arterial hypertension was classified according to the tricuspid regurgitation pressure gradient (TRPG) as mild (36-50 mmHg), moderate (51-75 mmHg), or severe (>75 mmHg). The RAA index was calculated as the RAA divided by body surface area.
Results:
The RAA index was higher in dogs with moderate PAH (13.3 cm2 /m2 ; range, 3.4-24.7 cm2 /m2 ) and severe PAH (12.1 cm2 /m2 ; range, 5.4-21.8 cm2 /m2 ) than in those with mild PAH (6.7 cm2 /m2 ; range, 4.8-10.7 cm2 /m2 ) or in controls (7.3 cm2 /m2 ; range, 4.2-10.2 cm2 /m2 ; P < 0.001). The RAA index was higher (P < 0.0001) in dogs with R-CHF (17.5 cm2 /m2 ; range, 12.7-24.7 cm2 /m2 ) compared to those without R-CHF (7.6 cm2 /m2 ; range, 4.4-19.4 cm2 /m2 ). The most accurate cutoff value of the RAA index to identify R-CHF was >12.3 cm2 /m2 (sensitivity, 100%; specificity, 89.5%). In dogs with PAH, severity of tricuspid regurgitation (TR) was the only independent predictor of RAA index based on multivariate analysis (P < 0.02).
Conclusions And Clinical Importance:
The RAA index can be used to evaluate right atrial size in dogs and may be more effective than TRPG in predicting R-CHF in dogs with PAH. The severity of TR is the main determinant of the RAA index in dogs with PAH.
More Related Videos
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...